BMS-303141

• CAT Number: I005616
• CAS Number: 943962-47-8
• Molecular Formula: C₁₉H₁₅Cl₂NO₄S
• Molecular Weight: 424.31
• Purity: ≥95%
• Synonyms: BMS303141;BMS 303141
• Target: ATP Citrate Lyase
• Solubility: DMSO: ≥ 47 mg/mL
• Storage: Store at -20C
• IC50: 0.13 uM
• IUPAC Name: 3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide
• InChI: InChI=1S/C19H15Cl2NO4S/c1-26-17-8-7-13(12-5-3-2-4-6-12)9-16(17)22-27(24,25)18-11-14(20)10-15(21)19(18)23/h2-11,22-23H,1H3
• InChIKey: SIIPNDKXZOTLEA-UHFFFAOYSA-N
• SMILES: COC1=C(C=C(C=C1)C2=CC=CC=C2)NS(=O)(=O)C3=CC(=CC(=C3O)Cl)Cl

BMS-303141(CAT: I005616) is a potent and selective inhibitor of ATP-citrate lyase (ACL), exhibiting an IC₅₀ of 0.13 µM against human recombinant ACL. ACL is a key enzyme in lipid metabolism, catalyzing the conversion of citrate to acetyl-CoA, a precursor for fatty acid and cholesterol biosynthesis. By inhibiting ACL, BMS-303141 reduces lipid synthesis and modulates energy metabolism, making it a valuable compound in metabolic disease research, particularly for studying obesity, type 2 diabetes, and dyslipidemia. Additionally, its role in altering lipid metabolism positions it as a promising agent in oncology research for targeting tumor growth dependent on lipid biosynthesis.